Loading…
Develops targeted oncology therapies, including an approved treatment for a rare form of lung cancer (Ibtrozi).
Develops targeted oncology therapies, including an approved treatment for a rare form of lung cancer (Ibtrozi).
Its marketed drug Ibtrozi, approved in the US in 2025, came through the 2024 purchase of AnHeart Therapeutics, and product revenue starts from that launch. Oncologists prescribe it for patients whose tumours carry a ROS1 gene change, and it uses cash and launch revenue to fund the rest of its pipeline.
Moat: none (IP / patents, regulatory licence). Newly approved targeted therapy for a genetically defined lung cancer subtype, in a competitive class.
Headquarters: New York City, US · Founded: 2018 · Employees: 298
Size Nuvation Bio (NUVB) is a United States Health Care company (Biotechnology) with a market value of $1.46B, the 2005th largest of 3,117 United States companies the cockpit tracks. Shares closed at $4.16 on 6 Nov 2026.
Performance Over six months the shares fell 13.2%, against -19.4% for the median peer and -1.1% for the United States market (cap-weighted) — 7th highest of 18 in its peer set.
Growth Revenue grew 1,083.6% over the last twelve months (peer median +21.1%); the operating margin is -81.0% (peer median -26.7%).
Valuation It trades at 7.2× enterprise value to sales against a peer median of 19.4× (7th cheapest of 16).
Credit Nuvation Bio has 1 bond outstanding ($288M).
Short interest Short interest is 18.0% of the free float (15 Oct 2026).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $170M | $62.9M | $7.87M | $0 | $0 |
| Revenue growth | — | +699% | — | — | — |
| Gross profit | $148M | $51.9M | $112,000 | -$222,000 | -$484,000 |
| EBITDA | -$135M | -$211M | -$167M | -$99.6M | -$119M |
| Net income | -$150M | -$205M | -$568M | -$75.8M | -$104M |
| Free cash flow | -$121M | -$174M | -$131M | -$68.1M | -$96.5M |
| Capital expenditure | $8.40M | $8.35M | $162,000 | $69,000 | $370,000 |
| Total debt | $416M | $213M | $8.91M | $4.01M | $4.26M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Nuvation Bio NUVB | $1.46B | -13% | +1,084% | -81% | 7.2× | n/a |
| Roche RO.SW | $385B | +22% | -1% | 31% | 5.6× | 0.9% |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 3.2× | -12.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NUVB | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.0% | -3.0% | 5th lowest of 21 |
| 6-month return | -13.2% | -19.4% | 7th highest of 18 |
| Distance from 52-week high | -57.3% | -40.7% | 3rd lowest of 21 |
| Revenue growth (TTM) | +1,083.6% | +21.1% | 3rd highest of 17 |
| Operating margin | -81.0% | -26.7% | 8th lowest of 17 |
| EV / Sales | 7.2× | 19.4× | 7th cheapest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nuvation Bio NUVB | United States | $1.46B | -13% | +1,084% | -81% | 7.2× | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.45B | -38% | n/a | n/a | n/a | n/a | n/a |
| Kardigan KARD | United States | $1.45B | n/a | n/a | n/a | n/a | n/a | n/a |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.49B | +126% | +5% | -1,720% | 1,640.0× | n/a | n/a |
| uniQure QURE | United States | $1.51B | -22% | +30% | -1,093% | 66.8× | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.41B | +43% | -13% | -359% | 743.5× | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.52B | -26% | +17% | 38% | 4.4× | -7.9% | +15.0% |
| Taysha Gene Therapies TSHA | United States | $1.41B | -36% | -32% | -2,855% | 184.6× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.53B | -41% | +25% | 33% | n/a | n/a | n/a |
| Hualan Biological Vaccine 301207.SZ | China | $1.39B | -21% | -28% | -7% | 10.3× | 36.5% | -13.1% |
| AnaptysBio ANAB | United States | $1.39B | -33% | +93% | 56% | 6.3× | -1.2% | +25.6% |
| Oncolys BioPharma 4588.T | Japan | $1.39B | +162% | +1,662% | -303% | 429.8× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 1.8× | -4.1% | +33.5% |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.38B | -19% | +1% | 10% | 3.8× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | 199.0× | n/a | n/a |
| Mineralys Therapeutics MLYS | United States | $1.36B | -48% | n/a | n/a | n/a | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | 20.6× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | 2.7× | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 19.4× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 3.3× | n/a | n/a |
Nuvation Bio has 1 bond outstanding with $288M face value.